Tag Archives: PSMATargeted

FDA Approves Pylarify (piflufolastat F 18) PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer

FDA Approves Pylarify (piflufolastat F 18) PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer May 27, 2021 — FDA has approved Pylarify (piflufolastat F 18) – a drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. With the approval of Pylarify, certain men with prostate… Read More »